Loading... Please wait...
Sort by:

therapy-trends-jpg.jpg
Therapy Trends
 reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

  • Future Innovations in Oncology: Early Stage Outlook [2018]
    Learn More Future Innovations in Oncology: Early Stage Outlook [2018]
    How is the Oncology treatment landscape expected to evolve over the next 10 years? Oncology treatment has undergone a dramatic shift over the past 20 years with many drugs entering the space greatly improving survival...
  • Renal Cell Carcinoma: KOL Insight [2018]
    Learn More Renal Cell Carcinoma: KOL Insight [2018]
    RCC: A new era of IO-based combination therapy The recent FDA approval of BMS’ Opdivo/Yervoy has pioneered a new immuno-oncology (IO)-based combination approach to the first-line treatment of RCC. How do KOLs view...
  • Multiple Myeloma: KOL Insight [2018]
    Learn More Multiple Myeloma: KOL Insight [2018]
    How do the multitude of emerging combination regimens stack up in MM? The treatment of multiple myeloma (MM) is rapidly evolving and the range of combination therapies is set to diversify with triplet and quadruple...
  • Gastric Cancer: KOL Insight [2018]
    Learn More Gastric Cancer: KOL Insight [2018]
    All change in the gastric cancer treatment landscape? KOLs speak out… The treatment of gastric cancer is rapidly evolving and the range of therapies is set to diversify with the approval and introduction of novel...
  • Nonalcoholic Steatohepatitis (NASH): KOL Insight [2018]
    Learn More Nonalcoholic Steatohepatitis (NASH): KOL Insight [2018]
    Are novel therapies set to revolutionise NASH? No drug therapies have been approved for patients with nonalcoholic steatohepatitis (NASH) but this could all change in the next 3-5 years. Four late-stage pipeline...
  • Breast Cancer: KOL Insight [2018]
    Learn More Breast Cancer: KOL Insight [2018]
    How is biosimilar trastuzumab expected to fare in breast cancer? Biosimilar trastuzumab is now available in Europe, and key opinion leaders (KOLs) weigh in on how this product is expected to fare after years of...
  • CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2018]
    Learn More CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2018]
    How are CAR-T cell therapies revolutionising treatment of haematological cancer? Last year witnessed the FDA approval of the first two anti-CD19 CAR-T cell therapies in two types of blood cancer. Find out how these...
  • Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight [2018]
    Learn More Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight [2018]
      Established brands, generics, biologics and new MOAs fight for supremacy in the COPD treatment landscape Established treatments are coming under pressure from generics, new combinations, biologics and new MOAs...
  • Ovarian Cancer: KOL Insight [2018]
    Learn More Ovarian Cancer: KOL Insight [2018]
    How will new combination regimens impact the ovarian cancer treatment landscape? PARP inhibitors are firmly entrenched in the treatment algorithm for ovarian cancer, and their role continues to diversify. How will...
  • Rheumatoid Arthritis: KOL Insight [2018]
    Learn More Rheumatoid Arthritis: KOL Insight [2018]
    How is Olumiant impacting the RA treatment landscape? After several years on the US market, the availability of Pfizer’s Xeljanz in the EU is generally welcomed by KOLs; however, Eli Lilly/Incyte’s Olumiant...
  • Head and Neck Squamous Cell Carcinoma: KOL Insight [2018]
    Learn More Head and Neck Squamous Cell Carcinoma: KOL Insight [2018]
    The HNSCC armamentarium is rapidly evolving. Where will IO move next? BMS’ Opdivo and Merck & Co.’s Keytruda have transformed the second-line therapy of recurrent/metastatic head and neck squamous cell...
  • Glioblastoma: KOL Insight [2018]
    Learn More Glioblastoma: KOL Insight [2018]
    Are novel therapies set to revolutionise glioblastoma? There has been little progress in the treatment of glioblastoma (GBM) for decades, and management of patients continues to remain challenging. ​N​ovel treatment...
  • Acute Myeloid Leukaemia: KOL Insight [2018]
    Learn More Acute Myeloid Leukaemia: KOL Insight [2018]
    How will four newly approved therapies transform treatment of AML? For decades, there were no approved treatments for acute myeloid leukaemia (AML) other than chemotherapies. The past year has witnessed the approval of...
  • Targeted Therapies in Asthma: KOL Insight [2018]
    Learn More Targeted Therapies in Asthma: KOL Insight [2018]
    Can new biologics breathe fresh competition into the targeted asthma treatment landscape? The severe asthma treatment landscape is evolving. Near-term debates will focus on how best to use currently approved treatments,...
  • Melanoma: KOL Insight [2017]
    Learn More Melanoma: KOL Insight [2017]
    Are novel therapies set to revolutionise malignant melanoma? Despite advances in the treatment of malignant melanoma (MM), demand still persists for improved modalities and outcomes. Newer targeted and immunotherapy...
  • Multiple Sclerosis: KOL Insight [2017]
    Learn More Multiple Sclerosis: KOL Insight [2017]
    How will Ocrevus reshape the MS treatment landscape? A multitude of recent approvals and launches are changing the way MS is treated, but what does the future hold? Key opinion leaders (KOLs) are excited about...
  • Alzheimer's Disease: KOL Insight [2017]
    Learn More Alzheimer's Disease: KOL Insight [2017]
    Do KOLs see a future for beta-amyloid as a target in Alzheimer’s? Despite the inexorable attrition rate, both big pharma and small biotechs continue to invest in Alzheimer’s disease R&D. Is the amyloid...
  • Prostate Cancer: KOL Insight [2017]
    Learn More Prostate Cancer: KOL Insight [2017]
    How will established and emerging agents reshape the prostate cancer treatment landscape? A multitude of novel therapies have been approved for prostate cancer over the past ten years, but what does the future hold? Key...
  • Ulcerative Colitis: KOL Insight [2017]
    Learn More Ulcerative Colitis: KOL Insight [2017]
    Will oral therapies transform the treatment of ulcerative colitis? With Pfizer’s Xeljanz (tofacitinib) pending approval in the US, new oral therapies are set to transform the ulcerative colitis (UC) treatment...
  • Colorectal Cancer: KOL Insight [2017]
    Learn More Colorectal Cancer: KOL Insight [2017]
    Will new targeted therapies transform the treatment of colorectal cancer? Checkpoint inhibitors continue their march into multiple areas of oncology, and are now approved as treatments for colorectal cancer. But while...

customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved